Next Article in Journal
RNA-Binding Protein MAC5A Is Required for Gibberellin-Regulated Stamen Development
Next Article in Special Issue
Tumor-Specificity, Neurotoxicity, and Possible Involvement of the Nuclear Receptor Response Pathway of 4,6,8-Trimethyl Azulene Amide Derivatives
Previous Article in Journal
Aging, Cellular Senescence, and Alzheimer’s Disease
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 23
Issue 4
10.3390/ijms23042008
Review Report
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

Piperlongumine as a Neuro-Protectant in Chemotherapy Induced Cognitive Impairment

Int. J. Mol. Sci. 2022, 23(4), 2008; https://doi.org/10.3390/ijms23042008
by Fabio Ntagwabira 1,2,3, Madison Trujillo 1,2,3, Taylor McElroy 1,2,3, Taurean Brown 1,2,3, Pilar Simmons 1,2, Delawerence Sykes 4 and Antiño R. Allen 1,2,3,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Int. J. Mol. Sci. 2022, 23(4), 2008; https://doi.org/10.3390/ijms23042008
Submission received: 29 December 2021 / Revised: 5 February 2022 / Accepted: 7 February 2022 / Published: 11 February 2022
(This article belongs to the Special Issue Cytotoxicity on Pharmaceutical Interactions in Chemotherapy)

Round 1

Reviewer 1 Report

The manuscript by Ntagwabira et al. addresses a significant issue linked with chemotherapy, which is cognitive impairment following treatment. The research examines the potential use of piperlongumine, an alkaloid with senolytic, anti-inflammatory and selective cytotoxic properties, as a neuroprotective agent against chemotherapy-induced cognitive impairment associated with the docetaxel-doxorubicin-cyclophosphamide (TAC) regimen.

Minor comments:

  1. The introduction should be checked for mistakes or missing words, for instance: line 40: ‘The need therapies that can prevent or alleviate these side effects is thus crucial’, line 77: ‘improves cognition in an and aged mice’.
  2. There are some unnecessary spaces throughout the entire manuscript: lines 55, 66, 77, 78, 110.
  3. Other minor mistakes include: line 97: ‘in the weeks of week 2 and week 6’, line 194: ‘indicate a significant decreases’, line 197: ‘a decrease from DMSO to PL (p<0.05), DMSO to PL (p<0.001)’, line 210: ‘PL and TAC treatment decreased Gria2 mRNA levels’ (the graph shows the opposite), line 215: ‘A In the current study’.

The manuscript is complex, well written, the research methods chosen for this study are adequate, the results are well presented and discussed, and the work lies within a topic of high current interest. Consequently, it is my opinion that this manuscript will be suitable for publication in International Journal of Molecular Sciences, subject to minor revisions.

 

Author Response

The entire manuscript was checked and corrected for spelling and punctuation mistakes, missing words, and unnecessary spaces. Line 252 ‘PL and TAC treatment increased Gria2 mRNA levels’ was corrected to reflect the graph 8 (C). Missing words in line 80 were added and the references Go et al. were corrected in text and reference list.

Reviewer 2 Report

In the present manuscript Ntagwabira et al. investigated the neuroprotective effect of piperlongumine on cognitive impairment during chemiotherapy. Overall, the manuscript is well designed and written. The topic is extremely interesting and of great relevance.

Author Response

Per referees’ recommendations, the entire manuscript was checked and corrected for spelling and punctuation mistakes, missing words, and unnecessary spaces. Line 252 ‘PL and TAC treatment increased Gria2 mRNA levels’ was corrected to reflect the graph 8 (C). Missing words in line 80 were added and the references Go et al. were corrected in text and reference list.

Back to TopTop